Saraclodium zeae biocontrol platform for mycotoxin reduction in maize

Overview

This research initiative focuses on developing Saraclodium zeae, a naturally occurring protective endophyte of maize, into a targeted biocontrol agent that reduces contamination from harmful mycotoxins. The endophyte produces pyrrocidines A and B, selective antifungal metabolites that have demonstrated significant in vitro activity against key maize pathogens including Fusarium verticillioides and Aspergillus flavus, which are responsible for producing the potent mycotoxins fumonisin and aflatoxin respectively.

The core value proposition is selectivity: pyrrocidine A shows strong activity against maize pathogens while exhibiting significantly reduced impact on beneficial endophytes. This selectivity positions S. zeae as a promising candidate for integrated pest and mycotoxin management strategies in commercial maize production, offering a biological alternative to conventional fungicides.

Technical specifications

Key features:

• Selective antifungal activity: Pyrrocidine A demonstrates minimum inhibitory concentration below 2 µg/mL against target pathogens, exceeding the potency of the commercial antifungal nystatin, while showing MIC values above 50 µg/mL against beneficial endophytes
• Broad isolate coverage: Pyrrocidines A and B are produced by more than 50 S. zeae isolates, representing over 34% of those screened
• Dual pathogen targeting: Activity against both Fusarium verticillioides (fumonisin producer) and Aspergillus flavus (aflatoxin producer)

Research approach:

• Whole genome sequencing and annotation of S. zeae to enable predictive analysis
• Identification and classification of all secondary metabolite biosynthetic gene clusters
• Development of a transformation protocol for genetic manipulation
• Biosynthetic pathway elucidation through gene knock-out and heterologous expression studies
• Transcriptomic profiling of S. zeae during interactions with maize and pathogenic fungi
• Comprehensive metabolite characterization via heterologous expression and transcription factor over-expression
• Toxicity evaluation of all identified metabolites

Technology readiness level

This research is at an early discovery stage (TRL 2-3). While the selective antifungal properties of pyrrocidines have been validated in vitro, significant work remains to fully characterize the secondary metabolite profile of S. zeae and to confirm the absence of unintended mycotoxin production. The planned genomic, transcriptomic, and heterologous expression studies will be essential for advancing this platform toward field validation and eventual commercial development as a biocontrol product.